for Russian partners
scientific and manufacturing capabilities
-
Innovative platformsDevelopment of mRNA technologies and biotechnological medicines -
Scientific researchJoint projects in socially significant therapeutic areas, including oncology, orphan diseases and vaccine prevention. -
Localization of productionThe full-cycle production of medicines and vaccines in Russia — from technology transfer to the production of finished dosage forms -
Educational initiativesRaising awareness of medical community and patients on the prevention and treatment of socially significant diseases
N.F. Gamaleya Center
2025development of mRNA-platforms
Strategic cooperation with the N.F. Gamaleya NRCEM to enable collaborative scientific research in cancer-related issues and to investigate the potential of the combination therapy of mRNA-based biotechnological medications with camrelizumab (Areima®).
Sechenov University
2025increasing access to innovative domestic medicines
A Cooperation agreement with Sechenov University to develop efficient cooperative solutions to accelerate import substitution in the pharmaceutical industry and create more opportunities for Russian patients to access innovative medications. The partners are jointly conducting research on biopharmaceuticals for rare and oncological diseases, as well as vaccines against high-consequence infectious diseases.
Government of Moscow Region
2025localization of full-cycle manufacturing of a vaccine against meningococcal infection
The partnership aims to foster entrepreneurship and innovative technologies in the Moscow Region and to implement Russia’s first full-cycle manufacturing project for a vaccine against meningococcal infection, including in-house synthesis of the drug substance.
Union of Russian Pediatricians
2026developing a culture of vaccination and immunoprophylaxis programs
A cooperation agreement with The Union of Russian Pediatricians aimed at raising awareness about vaccine prevention of infectious diseases. The partnership combines the expert potential of the professional medical community with the practical experience of the pharmaceutical industry to implement educational and awareness-raising projects at both federal and regional levels.
Presidential Academy
2026assessing the pharmaceutical industry’s contribution to Russia’s development
А cooperation agreement with the Presidential Academy (RANEPA) aimed at assessing the contribution of Russia’s pharmaceutical industry to the country’s economic and scientific development, as well as to strengthening pharmaceutical sovereignty. The collaboration will result in concrete expert recommendations aimed at improving public policy, including approaches to pharmaceutical provision for citizens.
